Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reno Debets

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Clinical & Developmental Immunology|March 9, 2012
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targetsTrudy Straetemans, Mandy van Brakel, Sabine van Steenbergen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2013
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicityCor Hj Lamers, Stefan Sleijfer, Sabine van Steenbergen, et al.
Cancers|June 2, 2021
V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple MyelomaPim Mutsaers, Hayri E Balcioglu, Rowan Kuiper, et al.
Human Gene Therapy Methods|November 26, 2014
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitnessCor H J Lamers, Sabine van Steenbergen-Langeveld, Mandy van Brakel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytesNiels Schaft, Ralph A Willemsen, Jolanda de Vries, et al.
Blood|August 18, 2016
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantationCor H J Lamers, Rebecca Wijers, Cornelis A M van Bergen, et al.
ERJ Open Research|December 21, 2019
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysisDeirdre M H J Ten Berge, Daniel P Hurkmans, Ilse den Besten, et al.
Clinical and Translational Radiation Oncology|February 13, 2026
HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trialPascal A Gunsch, Michiel Kroesen, Reno Debets, et al.
Viruses|August 15, 2014
Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating gliomaRutger K Balvers, Zineb Belcaid, Sanne K van den Hengel, et al.
Cytotherapy|February 8, 2013
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cellsCor H J Lamers, Pascal van Elzakker, Sabine C L van Steenbergen, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Clinical & Developmental Immunology|March 9, 2012
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targetsTrudy Straetemans, Mandy van Brakel, Sabine van Steenbergen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2013
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicityCor Hj Lamers, Stefan Sleijfer, Sabine van Steenbergen, et al.
Cancers|June 2, 2021
V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple MyelomaPim Mutsaers, Hayri E Balcioglu, Rowan Kuiper, et al.
Human Gene Therapy Methods|November 26, 2014
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitnessCor H J Lamers, Sabine van Steenbergen-Langeveld, Mandy van Brakel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytesNiels Schaft, Ralph A Willemsen, Jolanda de Vries, et al.
Blood|August 18, 2016
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantationCor H J Lamers, Rebecca Wijers, Cornelis A M van Bergen, et al.
ERJ Open Research|December 21, 2019
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysisDeirdre M H J Ten Berge, Daniel P Hurkmans, Ilse den Besten, et al.
Clinical and Translational Radiation Oncology|February 13, 2026
HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trialPascal A Gunsch, Michiel Kroesen, Reno Debets, et al.
Viruses|August 15, 2014
Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating gliomaRutger K Balvers, Zineb Belcaid, Sanne K van den Hengel, et al.
Cytotherapy|February 8, 2013
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cellsCor H J Lamers, Pascal van Elzakker, Sabine C L van Steenbergen, et al.
Pageof 14